Zomedica Reports 35% Growth in Q1 Revenues

Zomedica Corp. has announced a 35% year-over-year increase in first-quarter revenues, reaching a record $8.8 million. The company's growth has been driven by strong performances from therapeutic devices and its diagnostic offerings, notably the TRUFORMA® platform. Additionally, the newly formed Development Services segment contributed $2.0 million in revenue.

The company has introduced its AI-powered TRUVIEW® platform and established a collaboration with Boehringer Ingelheim to enhance equine diagnostics. Despite facing historical cash burn challenges in Q1, reductions of 15% were achieved compared to 2025. Gross margins stood at 62% for the quarter, and the company maintained $47.5 million in liquidity.

Operating expenses were reduced by 21%, aided by efficient management and absence of impairment charges. International sales reported steady growth, setting a robust revenue foundation for forthcoming quarters. Overall, Zomedica is positioned well to continue executing its growth strategy globally.